Pharmaceutical Practices and Patient Outcomes
Pharmaceutical Practices and Patient Outcomes is a research topic within Geriatrics and Gerontology. Science Explorer counts 44k research works in it since 1950. 11.6% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the challenges and consequences of polypharmacy, inappropriate medication use, and adverse drug events in the elderly population. It explores topics such as potentially inappropriate prescribing, pharmacist interventions, medication reconciliation, deprescribing, and the impact of anticholinergic burden. The research aims to address the complexities of medication management in older adults and improve patient outcomes.
- Polypharmacy
- Inappropriate Medication Use
- Elderly
- Adverse Drug Events
- Potentially Inappropriate Prescribing
- Pharmacist Intervention
- Medication Reconciliation
- Deprescribing
- Anticholinergic Burden
- Clinical Pharmacy Services
- Research works
- 44k fractional, since 1950
- In the world top 10%
- 5.2k per year above
- Top-10% rate
- 11.6% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +30% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Pharmaceutical Practices and Patient Outcomes research?
By volume, the United States and the United Kingdom publish the most (2.4k and 682 works in 2022–2025).
By volume, 2022–2025
- 1 United States 2.4k works
- 2 United Kingdom 682 works
- 3 India 478 works
- 4 France 384 works
- 5 Australia 371 works
- 6 Spain 298 works
- 7 Indonesia 289 works
- 8 Canada 270 works
- 9 Saudi Arabia 250 works
- 10 China 227 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Pharmaceutical Practices and Patient Outcomes research?
By volume in 2022–2025, University of North Carolina at Chapel Hill publishes the most Pharmaceutical Practices and Patient Outcomes research, followed by The University of Sydney and American Pharmacists Association.
By volume, 2022–2025
- 1 University of North Carolina at Chapel HillUnited States 64 works
- 2 The University of SydneyAustralia 39 works
- 3 American Pharmacists AssociationUnited States 35 works
- 4 Qatar UniversityQatar 29 works
- 5 Monash UniversityAustralia 29 works
- 6 University College CorkIreland 28 works
- 7 University of Wisconsin–MadisonUnited States 26 works
- 8 University of PittsburghUnited States 23 works
- 9 Airlangga UniversityIndonesia 23 works
- 10 Auburn UniversityUnited States 23 works
Who are the leading researchers in Pharmaceutical Practices and Patient Outcomes?
The most-cited researchers publishing on Pharmaceutical Practices and Patient Outcomes include Dan J. Stein and Aziz Sheikh.
- 1 Dan J. Stein South Africa 7.7k citations
- 2 Aziz Sheikh United Kingdom 5.8k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Pharmaceutical Practices and Patient Outcomes research done?
The largest centres of Pharmaceutical Practices and Patient Outcomes research in 2022–2025 are London (United Kingdom), Riyadh (Saudi Arabia), Paris (France) and Melbourne (Australia).
Largest cities, 2022–2025
- 1 London United Kingdom 155 works
- 2 Riyadh Saudi Arabia 99 works
- 3 Paris France 81 works
- 4 Melbourne Australia 80 works
- 5 Washington D.C. United States 79 works
- 6 Boston United States 78 works
- 7 Sydney Australia 77 works
- 8 Chapel Hill United States 74 works
- 9 New York United States 73 works
- 10 Baltimore United States 63 works
Where is the best place to study Pharmaceutical Practices and Patient Outcomes?
Among universities, judged by research, Qatar University, University of Gondar and University College Cork score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Qatar UniversityQatar | 66.3 | 17.0% | 11.4× | 29 | +77.5% |
| 2 | University of GondarEthiopia | 66.2 | 21.6% | 10.5× | 14 | +912.6% |
| 3 | University College CorkIreland | 65.2 | 15.3% | 12.7× | 28 | +126.8% |
| 4 | Royal College of Surgeons in IrelandIreland | 59.5 | 12.4% | 15.9× | 11 | +198.6% |
| 5 | University of Science and Technology of FujairahUnited Arab Emirates | 57.5 | 9.0% | 174.6× | 19 | — |
| 6 | Hindu College of PharmacyIndia | 55.0 | 18.2% | 17.4× | 16 | — |
| 7 | University of Science and TechnologyYemen | 54.1 | 8.8% | 17.8× | 16 | — |
| 8 | Jordan University of Science and TechnologyJordan | 52.9 | 12.2% | 9.5× | 14 | +97.2% |
| 9 | The University of SydneyAustralia | 52.7 | 18.6% | 4.6× | 39 | +49.9% |
| 10 | Newcastle UniversityUnited Kingdom | 52.6 | 16.9% | 4.7× | 16 | +383.3% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Pharmaceutical Practices and Patient Outcomes research growing?
Output in 2018–2022 was 30% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Pharmaceutical Practices and Patient Outcomes.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.